# US 2013/0171662 A1 · Assay

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0171662 A1
- Document ID: US20130171662A1
- Status: Published application
- Kind: A1
- Application number: 13/512,823
- Filed: 2010-12-15
- Published: 2013-07-04
- Earliest claimed: 2009-12-15
- Assignees: Cytosystems Limited
- Inventors: Ronald Alfred Laskey
- Web page: https://patentgrep.com/patent/US20130171662A1

## CPC

- G01N 33/57555: of the prostate
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/723: Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This disclosure relates to a diagnostic/prognostic assay for prostate cancer and including kits used in said assay.

## Claims

### Claim 1

A diagnostic or prognostic assay for the detection of prostate cancer cells in a biological sample comprising the steps:
i) obtaining an isolated cell sample from said biological sample and contacting the isolated cell sample with a binding agent that specifically binds at least one MCM polypeptide;
ii) contacting the isolated cell sample with a further binding agent that specifically binds an androgen receptor polypeptide [AR];
optionally iii) contacting the isolated cell sample with a still further binding agent that specifically binds prostate specific antigen [PSA];
iv) detecting the binding of two or more binding agents; and
v) determining the number of cells in said isolated cell sample that positively bind two or more binding agents, wherein the number of positive cells is an indicator of the presence of prostate cancer cells in the biological sample.

### Claim 2 (depends on 1)

An assay according to claim 1, wherein said MCM polypeptide is selected from the group consisting of: MCM2, MCM3, MCM4, MCM5, MCM6 or an MCM7 polypeptide.

### Claim 3 (depends on 2)

An assay according to claim 2 wherein said MCM polypeptide is MCM2 and/or MCM7.

### Claim 4 (depends on 2, 3)

An assay according to claim 2 or 3 wherein said MCM polypeptide is MCM2.

### Claim 5 (depends on 2, 3)

An assay according to claim 2 or 3 wherein said MCM polypeptide is MCM7.

### Claim 6 (depends on 3)

An assay according to claim 3 wherein said MCM polypeptide is MCM2 and MCM7.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

An assay according to any of claims 1-6 wherein said MCM polypeptide is represented by the amino acid sequence in FIG. 1, 2, 3, 4, 5 or 6.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

An assay according to any of claims 1-7 wherein said cell sample is contacted with a binding agent that specifically binds AR and a binding agent that specifically binds PSA.

### Claim 9 (depends on 8)

An assay according to claim 8 wherein said assay detects at least one MCM polypeptide, AR and PSA.

### Claim 10 (depends on 9)

An assay according to claim 9 wherein said assay detects MCM2 and/or MCM7, AR and PSA.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

An assay according to any of claims 1-10 wherein steps (ii) and (iii) are reversed.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

An assay according to any of claims 1-11 wherein said binding agent is a monoclonal antibody, or active binding fragment thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

An assay according to any of claims 1-12 wherein said biological sample is a sample of isolated bodily fluid.

### Claim 14 (depends on 13)

An assay according to claim 13 wherein said bodily fluid is urine, semen or seminal fluid.

### Claim 15 (depends on 13, 14)

An assay according to claim 13 or 14 wherein said biological sample is a filtered wherein said filtered sample provides said isolated cell sample.

### Claim 16

A diagnostic or prognostic assay for the determination of prostate cancer in a subject comprising the steps:
i) obtaining a first isolated biological sample and contacting the sample with a binding agent that specifically binds PSA; optionally
ii) detecting the presence of PSA in said sample;
iii) obtaining a second biological sample from the subject, preparing an isolated cell sample and contacting said cell sample with first and second binding agents that specifically bind at least one MCM polypeptide and an androgen receptor polypeptide;
iv) detecting the presence of said MCM polypeptide[s] and androgen receptor; and
v) determining the number of cells in said isolated cell sample that positively bind both MCM and androgen receptor, wherein the number of positive cells is an indicator of the presence of prostate cancer cells.

### Claim 17 (depends on 16)

An assay according to claim 16 wherein said first biological sample comprises serum.

### Claim 18 (depends on 16)

An assay according to claim 16 wherein said second biological sample is urine or semen.

### Claim 19 (depends on 16, 17, 18)

An assay according to any of claims 16-18 wherein said MCM polypeptide is MCM2 and/or MCM7.

### Claim 20 (depends on 19)

An assay according to claim 19 wherein said MCM polypeptide is MCM2.

### Claim 21 (depends on 19)

An assay according to claim 19 wherein said MCM polypeptide is MCM7.

### Claim 22 (depends on 19)

An assay according to claim 19 wherein said MCM polypeptide is MCM2 and MCM7.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

An assay according to any of claims 1-22 wherein said detection of binding agents is by fluorescence emission.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

An assay according to any of claims 1-22 wherein said detection of binding agents is by enzymic means.

### Claim 25

A kit comprising first, second and third binding agents wherein said agents bind a MCM polypeptide, androgen receptor polypeptide and prostate specific antigen polypeptides respectively,

### Claim 26 (depends on 25)

A kit according to claim 25 wherein said binding agents are monoclonal antibodies.
